2020 American Society of Hematology Virtual Annual Meeting*

Download All
December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Expert faculty review and share their insights and perspectives on key findings in lymphomas and chronic lymphocytic leukemia presented at the 2020 ASH Annual Meeting.
Jeremy S. Abramson, MD, MMSc
John M. Burke, MD
Jeff P. Sharman, MD

Lymphomas and Chronic Lymphocytic Leukemia

Review expert perspectives on the most clinically relevant data on indolent and aggressive lymphomas presented at the 2020 ASH annual meeting.

John M. Burke, MD Jeff P. Sharman, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: February 26, 2021 Expired: February 25, 2022

In this commentary, Jeremy S. Abramson, MD, MMSc, discusses the presentations from ASH 2020 that he expects to affect practice in the management of patients with lymphomas/CLL.

Jeremy S. Abramson, MD, MMSc Released: March 11, 2021

Listen to Jeremy S. Abramson, MD, MMSc, discuss the presentations from ASH 2020 that he expects to affect practice in the management of patients with lymphomas/CLL.

Jeremy S. Abramson, MD, MMSc Released: March 26, 2021
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue